Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) COO Adrian Haigh sold 22,222 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $10.30, for a total transaction of $228,886.60. Following the completion of the transaction, the chief operating officer now directly owns 22,222 shares of the company's stock, valued at $228,886.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Fennec Pharmaceuticals Trading Down 5.5 %
FENC opened at $9.70 on Thursday. Fennec Pharmaceuticals Inc has a 12-month low of $6.30 and a 12-month high of $11.92. The firm has a market capitalization of $262.87 million, a PE ratio of -15.90 and a beta of 0.38. The firm has a 50 day moving average of $10.10 and a two-hundred day moving average of $9.33.
Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.12). The business had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million. As a group, analysts predict that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
Several brokerages recently commented on FENC. Wedbush reaffirmed an "outperform" rating and issued a $16.00 price objective on shares of Fennec Pharmaceuticals in a research report on Monday, March 18th. HC Wainwright raised their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Thursday, April 4th. Finally, Craig Hallum raised their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday, March 18th.
Check Out Our Latest Stock Report on Fennec Pharmaceuticals
Institutional Investors Weigh In On Fennec Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in FENC. Sonic GP LLC acquired a new stake in shares of Fennec Pharmaceuticals during the 4th quarter worth approximately $23,111,000. Vanguard Group Inc. grew its stake in shares of Fennec Pharmaceuticals by 1,294.3% during the 4th quarter. Vanguard Group Inc. now owns 1,140,063 shares of the company's stock worth $12,792,000 after purchasing an additional 1,058,295 shares during the period. BlackRock Inc. grew its stake in shares of Fennec Pharmaceuticals by 1,507.6% during the 2nd quarter. BlackRock Inc. now owns 830,119 shares of the company's stock worth $7,330,000 after purchasing an additional 778,481 shares during the period. State Street Corp acquired a new stake in shares of Fennec Pharmaceuticals during the 2nd quarter worth approximately $2,309,000. Finally, Geode Capital Management LLC grew its stake in shares of Fennec Pharmaceuticals by 909.3% during the 2nd quarter. Geode Capital Management LLC now owns 196,877 shares of the company's stock worth $1,738,000 after purchasing an additional 177,370 shares during the period. Institutional investors and hedge funds own 55.51% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
